Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-54175446 Drug Interaction Study
NCT03058419Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JNJ-54175446 in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Plasma Trough Concentration and 9 more. Started Mar 2017; status: completed.
02
Drugs
JNJ-54175446
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03058419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058419.